Progressive supranuclear palsy (PSP) atypical is a rare neurodegenerative disease belonging to the group of parkinsonisms. This condition is characterized by progressive dystonia, balance disorders, and specific motor and cognitive impairments. The main mechanism of the pathology is neurodegeneration of the ventromedial part of the brainstem and basal ganglia. Symptoms of PSP atypical manifest themselves in the form of severe motor impairments, unpleasant sensations and various mental disorders, which significantly worsens the quality of life of patients and creates difficulties in their adaptation to everyday life. Given the complexity of pathogenesis and the variety of clinical manifestations, correct diagnosis and treatment are defined as one of the primary tasks of neurology.
History of the disease and interesting historical facts
The history of progressive supranuclear palsy (PSP) goes back to the mid-20th century, when the disease was initially described as a syndrome characteristic of elderly people with parkinsonian manifestations. The main focus was on neurological symptoms, since the disease has much in common with Parkinson's disease. In 1964, neurologists John W. Stanley and Richard S. Cohen were the first to describe the clinical features of this disorder. An interesting fact is that PSP was initially considered a type of Parkinson's disease, but subsequent studies revealed typical atrophic changes in the brain that distinguished it from classic parkinsonism. The mechanisms underlying the pathology remained poorly understood until the end of the 20th century, when more data appeared on the genetic and molecular aspects of the disease. Gradually, PSP was identified as a separate nosological entity.
Epidemiology
The epidemiology of progressive supranuclear palsy atypical demonstrates a rather low incidence rate. According to current data, the prevalence of this disease is from 1 to 5 cases per 100,000 population. It is more common in elderly people, in particular, among people over 60 years old. Population studies have shown that among patients with primary parkinsonism, the diagnosis of PSP atypical is made only in 5–10% cases. The disease has no statistical attachment to racial or ethnic status, but some studies indicate a higher risk of development among women compared to men. It is important to note that the incidence rate may vary depending on the region, which is associated with socioeconomic factors and access to health care.
Genetic predisposition to this disease
Although PSP is largely considered a sporadic disorder, several genetic mutations have been identified that are associated with its development. The most significant are mutations in genes responsible for the synthesis of proteins involved in cellular protection and neuronal trophism. The main genes involved include:
- MAPT – encodes a tau protein that is involved in the organization of microtubules and stabilization of the neuronal cytoskeleton;
- PRNP - associated with neuronal death processes.
- GRN (progeria) – associated with the uncontrolled development of neurodegenerative processes;
- VCP – is involved in the regulation of cellular metabolism and affects cellular resistance to stress.
Mutations in these genes may increase susceptibility to neurodegeneration, but the exact mechanism by which they influence the development of atypical PSP is not yet fully understood.
Risk factors for the development of this disease
Several risk factors have been identified that may contribute to the development of progressive supranuclear palsy, atypical. These include:
- Age – the main risk factor for PNP is older age, especially after 60 years;
- Family history of disease – a history of neurodegenerative diseases in the family may increase the risk;
- Environmental factors – exposure to toxic chemicals and heavy metals such as lead and mercury can be potential triggers;
- Head injuries - repeated contusions can increase the chances of developing the disease.
- Lack of physical activity – a sedentary lifestyle is associated with various forms of neurodegeneration;
Understanding risk factors is important for developing effective strategies for prevention and early detection of atypical PNP.
Diagnosis of this disease
Diagnosis of progressive supranuclear palsy requires a comprehensive approach, including clinical assessment, laboratory and radiological methods. The main symptoms of the disease may include:
- Head exercise – problems with balance;
- Movement disorders – rigidity, bradykinesia;
- Difficulty with appetite and chewing;
- Change in emotional background – depression and apathy;
- Cognitive disorders – deterioration of memory and attention.
Laboratory tests may include a complete blood count, biochemistry, and vitamin and mineral levels. Radiological examination, particularly MRI, may reveal specific changes in the brain, such as basal ganglia atrophy. Other diagnostic methods may include neuropsychological testing to assess cognitive function. Differential diagnosis should include Parkinson's disease, vascular encephalopathies, and other forms of parkinsonism, which requires a thorough assessment of all clinical data.
Treatment
Treatment of progressive supranuclear palsy atypical is usually complex and aimed at reducing symptoms and improving the quality of life of patients. The main approaches to treatment include:
- General therapy – includes physical and occupational therapy to maintain motor skills;
- Pharmacological treatment – the use of drugs such as antiparkinsonian drugs and antidepressants;
- Surgical treatment – in some cases, deep brain stimulation may be considered;
- Other treatments include psychotherapy and education of the patient and family about the disease.
It is important that treatment should be carried out individually for each patient, taking into account the specifics of the disease and concomitant conditions.
List of medications used to treat this disease
Drugs used to treat atypical progressive supranuclear palsy include:
- Levodopa – to improve motor functions;
- Selegiline is a medicinal antidepressant;
- Antidotal drugs to relieve the effect of rigidity;
- Sedatives to reduce anxiety;
- Analgesics for pain control.
Each treatment should be agreed upon with the attending physician and take into account the individual characteristics of the patient, as well as potential side effects.
Disease monitoring
Monitoring of progressive supranuclear palsy is an important part of disease management and should include regular check-ups. This allows for timely detection of changes in the patient's condition and adjustment of therapy. The prognosis of the disease varies, but in most cases there is a slow progression of symptoms over 6-12 years after the onset of the disease. Complications may include:
- Swallowing problems that increase the risk of aspiration;
- Mental disorders that can lead to states of depression;
- Falls that cause injuries.
Maintaining a high quality of life and adapting to the condition can be achieved through ongoing monitoring and support from health professionals and loved ones.
Age-related features of the disease
Progressive supranuclear palsy atypical may manifest itself differently depending on the patient's age group. In older people, the disease often progresses more aggressively, which can lead to rapid deterioration of motor functions and cognitive status. At the same time, in younger patients, the disease may have less pronounced symptoms in the initial stages, but there is also a risk of more rapid progression. Given these features, it is important to carry out an individualized approach to diagnosis and therapy in different age groups.
Questions and Answers
- What is progressive supranuclear palsy? It is a rare neurodegenerative disease characterized by motor and cognitive impairment.
- What is the cause of the disease? The exact cause is unknown, but genetic and environmental factors are suspected.
- Is it possible to cure the disease? There is currently no universal treatment for PNP; symptomatic therapy and support are of primary importance.
- How is PNP diagnosed? Diagnosis includes clinical evaluation, laboratory tests, MRI, and neuropsychological testing.
- What is the prognosis for patients with PNP? The prognosis varies, the disease usually progresses over several years, but quality of life can be maintained with adequate therapy.
